亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

上海市柏際醫藥有限公司  

輪環藤寧等雜環類,胡椒環系類

搜索
新聞分類
  • 暫無分類
聯系方式
  • 聯系人:周女士
  • 電話:0513-89066587
  • 郵件:sales01@biogenepharm.com
  • QQ:1930575102
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 公司新聞 > Entresto - LCZ696 重磅出擊,心血管歷史突破
公司新聞
Entresto - LCZ696 重磅出擊,心血管歷史突破
2015-07-14IP屬地 火星52
 Entresto - LCZ696 產品學習
 
簡介:
entresto是結合sacubitril,一腦啡肽酶抑制劑,和纈沙坦,血管緊張素Ⅱ受體阻斷劑,以減少風險心力衰竭患者的心血管死亡及住院治療慢性心力衰竭(NYHA II-IV級)和射血分數降低。entresto通常與其他心力衰竭的聯合給藥治療,在ACE抑制劑或ARB的地方。
 
名稱:Entresto
研發代碼: LCZ696
3-(1-Biphenyl-4-ylMethyl-3-ethoxycarbonyl-1-butylcarbaMoyl)propionate-3'-Methyl-2'-(pentanoyl(2'-(tetrazol-5-ylate)biphenyl-4'-ylMethyl)aMino)butyrate
 
關鍵中間體:
一、 中文名: (R)-叔丁基 (1-([1,1'-聯苯]-4-基)-3-羥基丙烷-2-基)氨基甲酸酯
外文名  : (R)-tert-butyl (1-([1,1'-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbaMate
CAS : 1426129-50-1
分子式:C20H25NO3
分子量: 327.4174
用    途: LCZ696中間體
原研廠家: 諾華
供應商:臺州保隆
             捌捌七零貳佰伍叁
 
二、中文別名:LCZ696中間體N-3 / (2R,4S)-5-(聯苯-4-基)-4-[(叔丁氧基羰基)氨]-2-甲基戊酸
英文名稱:LCZ696 inter N-3 /(2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic acid
CAS號:1012341-50-2
 
©2025 上海市柏際醫藥有限公司 版權所有   技術支持:化工網   訪問量:3875  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |